Vir Biotechnology, Inc. (VIR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vir Biotechnology, Inc. (VIR) trades at $9.23 with AI Score 21/100 (Grade F). Vir Biotechnology, Inc. is a commercial-stage immunology company focused on developing therapeutic products for serious infectious diseases. Market cap: $1.56B, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 10, 2026Analyst Coverage for VIR: VIR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VIR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VIR: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Vir Biotechnology, Inc. (VIR) Healthcare & Pipeline Overview
Vir Biotechnology, Inc. is a commercial-stage immunology company specializing in developing antibody-based therapies for infectious diseases such as COVID-19, hepatitis B, influenza A, and HIV. The company leverages collaborations and licensing agreements to advance its pipeline and address unmet medical needs in the infectious disease space.
What Is the Investment Thesis for VIR?
Vir Biotechnology presents a compelling investment case based on its innovative approach to treating infectious diseases and its diversified pipeline of therapeutic candidates. The company's Sotrovimab demonstrated efficacy against COVID-19, generating significant revenue. Future growth is expected to be driven by the advancement of its HBV and influenza programs, particularly VIR-2218 and VIR-2482. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The company's gross margin stands at 275.2%. However, the company's negative profit margin of -676.0% indicates that it is not yet profitable. The company's beta of 1.66 suggests that the stock is more volatile than the market. Investors should monitor clinical trial data, regulatory decisions, and partnership developments to assess the company's long-term potential.
Based on FMP financials and quantitative analysis
VIR Key Highlights
- Vir Biotechnology has a market capitalization of $1.56B, reflecting investor valuation of its pipeline and technology.
- The company's gross margin is 275.2%, indicating strong pricing power on its commercialized products.
- Vir Biotechnology has a negative profit margin of -676.0%, reflecting substantial R&D investments and operating expenses.
- The company's beta is 1.66, indicating higher volatility compared to the broader market.
- Vir Biotechnology collaborates with leading pharmaceutical companies like GlaxoSmithKline and Gilead Sciences, validating its scientific approach.
Who Are VIR's Competitors?
VIR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $133.68 | -0.45% | $166B | 94 |
| JNJ Johnson & Johnson | $253.04 | +1.23% | $609B | 90 |
| MRNA Moderna, Inc. | $61.82 | -2.11% | $25.0B | — |
| INVA Innoviva, Inc. | $21.28 | -1.98% | $1.57B | 90 |
| XERS Xeris Biopharma Holdings, Inc. | $8.60 | -2.27% | $1.48B | 95 |
| ABCL AbCellera Biologics Inc. | $5.80 | -10.29% | $1.77B | 76 |
| GLPG Galapagos NV | $27.98 | +1.71% | $1.84B | 70 |
| HRMY Harmony Biosciences Holdings, Inc. | $33.50 | -0.80% | $1.94B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VIR's Key Strengths?
- Innovative antibody platform for infectious disease therapies.
- Strong pipeline of therapeutic candidates targeting unmet medical needs.
- Strategic collaborations with leading pharmaceutical companies.
- Experienced management team with expertise in immunology and drug development.
What Are VIR's Weaknesses?
- Reliance on partnerships for funding and development.
- Dependence on regulatory approvals for commercial success.
- Competition from established pharmaceutical companies.
- Negative profit margin.
What Could Drive VIR Stock Higher?
- Clinical trial results for VIR-2218 in hepatitis B virus (HBV) patients.
- Clinical trial results for VIR-2482 in influenza A prevention.
- Potential new partnerships or collaborations to expand the pipeline.
- Regulatory updates regarding the approval of VIR-2218 or VIR-2482.
What Are the Key Risks for VIR?
- Financial-distress signal — its Altman Z-Score of 1.80 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-53.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for key pipeline candidates.
- Regulatory setbacks or delays in approval processes.
- Competition from established pharmaceutical companies and biosimilars.
- Dependence on partnerships for funding and development.
- Intellectual property challenges or patent disputes.
What Are the Growth Opportunities for VIR?
- Growth opportunity 1: Development of VIR-2218 for Hepatitis B Virus (HBV): VIR-2218 is an RNAi therapeutic designed to suppress HBV replication. The global market for HBV treatments is expected to reach $4.2 billion by 2028. Successful clinical trials and regulatory approval could drive significant revenue growth for Vir Biotechnology. The company is also developing VIR-3434, another HBV treatment, which could further expand its market share.
- Growth opportunity 2: Advancement of VIR-2482 for Influenza A: VIR-2482 is a broadly neutralizing antibody targeting influenza A. The influenza vaccine market is estimated at $6.8 billion. VIR-2482 has the potential to provide superior protection compared to existing vaccines, driving adoption and market share gains. Clinical trials are ongoing to evaluate its efficacy and safety.
- Growth opportunity 3: Expansion of Sotrovimab (Xevudy) for COVID-19: While the COVID-19 pandemic has subsided, the need for effective treatments remains, particularly for vulnerable populations. Sotrovimab, marketed as Xevudy, is a SARS-CoV-2-neutralizing monoclonal antibody. Continued sales of Sotrovimab could provide a steady revenue stream for Vir Biotechnology. The company is also exploring next-generation COVID-19 therapies.
- Growth opportunity 4: Strategic Partnerships and Collaborations: Vir Biotechnology has established collaborations with leading pharmaceutical companies and research institutions. These partnerships provide access to innovative technologies, funding, and expertise. Continued strategic collaborations could accelerate drug development and expand the company's pipeline. The company's collaboration with Gilead Sciences for chronic hepatitis B virus is particularly promising.
- Growth opportunity 5: Development of VIR-1111 for HIV Prevention: VIR-1111 is an HIV prevention therapy. The global market for HIV prevention is substantial. Successful development and commercialization of VIR-1111 could generate significant revenue for Vir Biotechnology. The company is conducting preclinical and clinical studies to evaluate its safety and efficacy.
What Opportunities Does VIR Have?
- Expansion of its pipeline through internal research and development.
- Acquisition of complementary technologies and assets.
- Geographic expansion into emerging markets.
- Development of new therapies for emerging infectious diseases.
What Threats Does VIR Face?
- Clinical trial failures.
- Regulatory setbacks.
- Patent challenges.
- Competition from biosimilars and generic drugs.
What Are VIR's Competitive Advantages?
- Proprietary antibody platform for developing infectious disease therapies.
- Strong intellectual property portfolio protecting its therapeutic candidates.
- Strategic collaborations with leading pharmaceutical companies and research institutions.
- Expertise in immunology and infectious disease research.
What Does VIR Do?
Vir Biotechnology, Inc., founded in 2016 and headquartered in San Francisco, California, is dedicated to combating serious infectious diseases. The company's mission is to combine immunologic insights with cutting-edge technologies to create effective therapeutic and preventative solutions. Vir's pipeline includes programs targeting diseases such as COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its lead product, Sotrovimab (marketed as Xevudy), is a SARS-CoV-2-neutralizing monoclonal antibody developed for the treatment and prevention of COVID-19. Other key programs include VIR-2218 and VIR-3434 for HBV, VIR-2482 for influenza A, and VIR-1111 for HIV. Vir Biotechnology strategically collaborates with organizations like the Bill & Melinda Gates Foundation, the National Institutes of Health, Alnylam Pharmaceuticals, Brii Biosciences, WuXi Biologics, GlaxoSmithKline, and Gilead Sciences to accelerate its research and development efforts. These collaborations encompass licensing agreements, research collaborations, and manufacturing agreements, enabling Vir to leverage external expertise and resources to advance its therapeutic candidates through clinical development and commercialization.
What Products and Services Does VIR Offer?
- Develops antibody-based therapies for infectious diseases.
- Focuses on treatments and preventatives for COVID-19.
- Creates therapies for hepatitis B virus (HBV).
- Develops solutions for influenza A virus.
- Works on HIV prevention therapies.
- Collaborates with pharmaceutical companies and research institutions.
- Conducts clinical trials to evaluate the safety and efficacy of its therapies.
How Does VIR Make Money?
- Develops and commercializes therapeutic products for infectious diseases.
- Generates revenue through sales of its commercialized products, such as Sotrovimab.
- Partners with pharmaceutical companies to co-develop and commercialize its therapies.
- Receives grant funding from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health.
What Industry Does VIR Operate In?
Vir Biotechnology operates within the biotechnology industry, which is characterized by high growth potential and significant R&D investments. The market for infectious disease therapeutics is driven by the emergence of new pathogens, increasing antibiotic resistance, and the need for preventative vaccines and treatments. The competitive landscape includes established pharmaceutical companies and specialized biotech firms focused on specific disease areas. Vir Biotechnology differentiates itself through its focus on immunology and its diversified pipeline of antibody-based therapies. The company's collaborations with leading research institutions and pharmaceutical companies provide a competitive advantage in accessing innovative technologies and accelerating drug development.
Who Are VIR's Key Customers?
- Patients suffering from infectious diseases such as COVID-19, hepatitis B, influenza A, and HIV.
- Healthcare providers who prescribe and administer Vir Biotechnology's therapies.
- Government agencies and public health organizations that purchase and distribute Vir Biotechnology's products.
- Pharmaceutical companies that partner with Vir Biotechnology to co-develop and commercialize its therapies.
ROE -53%Key Financial Metrics
Return on equity for Vir Biotechnology, Inc. stands at -53.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -43.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -25.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.1%, the inverse of the P/E and a quick read on earnings relative to price.
Vir Biotechnology, Inc. (VIR) Valuation Context
Valued at $1.56B, VIR is classified as a small-cap stock. Relative to its peer group, VIR's quantitative score of 21/100 is below the peer average of 92/100.
Company Profile
Vir Biotechnology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO Marianne De Backer. VIR has traded publicly since 2019.
F-Score 3/9Financial Health
Vir Biotechnology, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.80 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Vir Biotechnology, Inc. revenue of about $161.9M for fiscal 2026, with EPS near $-1.93. The estimate reflects 4 contributing analysts.
VIR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Vir Biotechnology's future, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting the promising results from recent clinical trials.
- The company’s ongoing partnerships with major pharmaceutical firms have bolstered its credibility and future growth prospects.
- Market perception has improved as Vir continues to innovate in the biotech space, particularly in addressing infectious diseases.
Bear Case
- Concerns about the competitive landscape in the biotech sector are prevalent, with several companies launching similar therapies.
- Social sentiment shows skepticism regarding the timeline for product approvals, which could delay potential revenue streams.
- Recent discussions have highlighted volatility in the stock, causing some investors to question the stability of their investment.
- The broader market uncertainty surrounding biotech stocks may lead to increased selling pressure, impacting Vir's stock performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VIR Latest News
-
Earnings Scheduled For May 6, 2026
benzinga · May 6, 2026
-
Earnings Scheduled For November 5, 2025
benzinga · Nov 5, 2025
-
Earnings Scheduled For May 7, 2025
benzinga · May 7, 2025
-
Stocks That Hit 52-Week Highs On Friday
· Jan 17, 2020
VIR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VIR.
Price Targets
Wall Street price target analysis for VIR.
VIR MoonshotScore
What does this score mean?
The MoonshotScore rates VIR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Marianne De Backer
Chief Executive Officer
Marianne De Backer brings extensive experience in the pharmaceutical and biotechnology industries to her role as CEO of Vir Biotechnology. Prior to joining Vir, she held leadership positions at Bayer Pharmaceuticals, where she oversaw strategy, business development, and innovation. She has a proven track record of driving growth and building successful partnerships. De Backer holds a Ph.D. in biotechnology from Ghent University and an MBA from Vlerick Business School.
Track Record: Since becoming CEO of Vir Biotechnology, Marianne De Backer has focused on advancing the company's pipeline of infectious disease therapies and strengthening its strategic partnerships. She has overseen the continued development of VIR-2218 and VIR-2482, and has led efforts to expand the company's collaborations with Gilead Sciences and other leading pharmaceutical companies. Her leadership has been instrumental in driving the company's growth and innovation.
Vir Biotechnology, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for VIR?
VIR holds an AI Score of 21/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Vir Biotechnology, Inc. is a commercial-stage immunology company focused on developing therapeutic products for serious infectious diseases. Their pipeline includes treatments and preventatives …
What does Vir Biotechnology, Inc. do?
Vir Biotechnology, Inc. is a commercial-stage immunology company focused on developing therapeutic products to treat and prevent serious infectious diseases. The company's pipeline includes programs targeting diseases such as COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV).
What do analysts say about VIR stock?
Analyst consensus on Vir Biotechnology (VIR) stock is mixed, reflecting the inherent risks and potential rewards associated with biotechnology companies. Key valuation metrics include market capitalization and potential revenue from its pipeline products. Growth considerations center on the successful development and commercialization of its HBV and influenza programs, as well as continued sales of Sotrovimab. Investors should monitor analyst ratings and price targets to assess market sentiment and potential upside.
What are the main risks for VIR?
The main risks for Vir Biotechnology (VIR) include clinical trial failures, regulatory setbacks, and competition from established pharmaceutical companies. Clinical trial failures could significantly impact the company's pipeline and future revenue potential. Regulatory setbacks or delays in approval processes could delay the commercialization of its therapies. Competition from established pharmaceutical companies and biosimilars could erode market share.
What are the key factors to evaluate for VIR?
Vir Biotechnology, Inc. (VIR) holds an AI score of 21/100 (low). Not financial advice.
How frequently does VIR data refresh on this page?
VIR's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VIR's recent stock price performance?
Vir Biotechnology, Inc. (VIR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative antibody platform for infectious disease therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VIR overvalued or undervalued right now?
Vir Biotechnology, Inc. (VIR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VIR before investing?
Before investing in Vir Biotechnology, Inc. (VIR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the latest available reporting period.